507 Phase 1/2a randomized, double-blind, placebo-controlled study: Safety, pharmacokinetics, and efficacy outcome measures of inhaled gallium citrate (AR-501) in people with cystic fibrosis
| Autor: | Cohen, A., Lechtzin, N., McBennett, K., Murphy, P., Sears, E., Hoffman, L., Saavedra, M., Hisert, K., Stevens-Brogan, M., Plascencia, C., Deans, L., Kelson, A., Lovalenti, P., Woo, J., Truong, V., Jafri, H. |
|---|---|
| Zdroj: | In Journal of Cystic Fibrosis October 2022 21 Supplement 2:S286-S286 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect